6 completed, 1 recruiting. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Recruiting 1 |
Follow Skyrizi: new trials by email Literature Review of Skyrizi trials Research Report on Skyrizi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| High Dose Risankizumab for Psoriasis risankizumab - Psoriasis | Phase 2 | Completed | Oregon Medical Research Center | 20 | 2022-03-01 | 2025-10-24 |
| A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Risankizumab, Placebo for risankizumab - Hidradenitis Suppurativa | Phase 2 | Completed | AbbVie | 243 | 2019-06-03 | 2022-08-11 |
| A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171) risankizumab - Psoriatic Arthritis | Phase 2 | Completed | AbbVie | 145 | 2016-12-15 | 2019-05-28 |
| BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis risankizumab, placebo for risankizumab - Arthritis, Psoriatic | Phase 2 | Completed | AbbVie | 185 | 2016-04-01 | 2019-05-30 |
| Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis Risankizumab - Psoriasis | Phase 2 | Completed | AbbVie | 110 | 2014-11-20 | 2019-11-08 |
| BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS) placebo for risankizumab, risankizumab - Ankylosing Spondylitis (AS) | Phase 2 | Completed | AbbVie | 159 | 2014-01-28 | 2019-05-31 |
Arthritis, Psoriatic (3) · Psoriasis (2) · Spondylitis, Ankylosing (2) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Dermatomyositis (1) · Giant Cell Arteritis (1) · Granulomatosis with Polyangiitis (1) · Hidradenitis Suppurativa (1) · Lupus Erythematosus, Systemic (1) · Plaque, Amyloid (1) · Polymyalgia Rheumatica (1) · Polymyositis (1) · Rheumatic Diseases (1) · Spondylarthritis (1)
AbbVie (5) · NYU Langone Health (1) · Oregon Medical Research Center (1)
United States (3) · Australia (1) · Canada (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Spain (1)
Benjamin D Ehst, MD, PhD (1) · Jonathan Samuels, MD (1)
PMID 35931879, PMID 36178584, PMID 29945918, PMID 33512666, PMID 36892753
2014 (1), 2015 (1), 2016 (1), 2019 (1)